Sung Lee - 05 Jun 2026 Form 4 Insider Report for Tango Therapeutics, Inc. (TNGX)

Reporting relationship: Director
Issuer ticker: TNGX
Reported as of: 05 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Jun 2026, 17:49:24 UTC
Prior SEC filing: 05 May 2026
Next SEC filing: 29 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Julie Fogarty, as attorney-in-fact

Key filing fact

Sung Lee filed Form 4 for Tango Therapeutics, Inc. (TNGX) on 08 Jun 2026.

Key facts

This page summarizes Sung Lee's Form 4 filing for Tango Therapeutics, Inc. (TNGX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 08 Jun 2026, 17:49.

Change

Previous filing in this sequence was filed on 05 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001793200 Primary reporting owner

Lee Sung

Relationship: Director
Address: C/O TANGO THERAPEUTICS, INC.,, 201 BROOKLINE AVE., SUITE 901, BOSTON
Signature: /s/ Julie Fogarty, as attorney-in-fact
Signature date: 08 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TNGX transaction

Common Stock

Award

Transaction value
Shares: +570
Change %: +2.6%
Price: $0.000000^*
Shares after: 22,870
Date: 05 Jun 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TNGX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +3,570
Change %
Price: $0.000000^*
Shares after: 3,570
Date: 05 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,570
Exercise price: $20.22
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

Footnote F2

This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

SEC remarks

Exhibit 24: Power of Attorney